In January 2011, we blogged about ABSORB, a  bioresorbable stent, when it received CE approval for use in Europe. Drug-eluting stents (DES) are composed of a metal scaffold that is coated with a polymer containing an antiproliferative agent , which is released gradually over the weeks to months after the stent is inserted.  The durable polymer residue…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Following the approval last October of dabigatran, some observers criticized the FDA’s decision not to approve the lower 110 mg dose of the drug in addition to the higher 150 mg dose. Now, in a perspective in the New England Journal of Medicine, 3 FDA officials — B. Nhi Beasley, Ellis Unger, and Robert Temple — explain…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

The difference in stroke mortality among countries in Europe and Central Asia is large and, somewhat surprisingly, is growing larger, according to a new analysis of data from the World Health Organization. In a paper published online in the European Heart Journal, Josep Redon and colleagues examine recent 15-year trends from 39 countries. They report…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

The novel anticoagulant rivaroxaban is successful in preventing venous thromboembolism (VTE) in acutely ill medical patients, but a high bleeding rate means the drug probably won’t be used for this indication. Alexander Cohen, presenting the results of the MAGELLAN trial at the ACC in New Orleans, explained by way of background that 50% to 70%…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

The AHA is offering new guidance for the management of patients with pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension. The scientific statement is published online in Circulation. In addition to advice about anticoagulant therapy, the statement offers extensive recommendations about the appropriate use of fibrinolytic agents, catheter-based and surgical interventions, and…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Lowering blood pressure with an angiotensin-receptor blocker in patients with acute stroke and hypertension produces no benefits, according to a new study presented at the International Stroke Conference and published simultaneously online in the Lancet. In the Scandinavian Candesartan Acute Stroke Trial (SCAST), investigators randomized 2029 acute stroke patients in 9 north European countries who had a…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Analysis of data from the Heart Protection Study (HPS) indicates that a CRP measurement obtained at baseline does not predict the effect of statin therapy. In a paper published online in the Lancet, the HPS Collaborative Group report the results of the more than 20,000-patient HPS study based on CRP category at baseline. As previously reported,…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

High levels of HDL are linked to a lower risk for Alzheimer’s disease (AD), according to a new study published in Archives of Neurology. Researchers at Columbia University followed 1,130 Medicare recipients in New York City with no cognitive impairment. After 4,469 person-years of follow-up, they identified 101 cases of AD (89 probable and 12…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

In the EINSTEIN-DVT noninferiority study, 3449 patients with acute DVT were randomized to receive open label oral rivaroxaban or conventional therapy with enoxaparin followed by warfarin or acenocoumarol for 3, 6, or 12 months. The rate of recurrent VTE, the primary efficacy outcome, was lower with rivaroxaban treatment than with enoxaparin treatment, successfully demonstrating noninferiority for…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Performance measures to improve the diagnosis and treatment of peripheral artery disease (PAD) in adults have been published for the first time. The document was produced by the ACC, the AHA, and several other medical organizations. Here are a few key details of the performance measures: Measuring the ankle brachial index (ABI) is an easy…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.